Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells

Human Immunology

Volumn 70, Issue 10, 2009, Pages 854-857

  Bernal, Mónica ^a   Garrido, Pilar ^a   Jiménez, Pilar ^a   Carretero, Rafael ^a   Almagro, Manuel ^a   López, Pilar ^a   Navarro, Pilar ^a   Garrido, Federico ^a   Ruiz Cabello, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

CD95; HLA; MICA B; Monoclonal gammopathy of undetermined significance; Multiple myeloma

Indexed keywords

FAS ANTIGEN; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR;

ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOGENETICS; IMMUNOPHENOTYPING; IMMUNOSURVEILLANCE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL;

ANTIGENS, CD95; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, INNATE; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; PARAPROTEINEMIAS; RECEPTORS, KIR; RECEPTORS, NATURAL CYTOTOXICITY TRIGGERING; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 70349336692     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.07.004     Document Type: Article

References (16)

1. Bladé J., Rosiñol L., Cibeira M.T., and de Larrea C.F. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22 (2008) 1651-1657
2. Teng M.W., Swann J.B., Koebel C.M., Schreiber R.D., and Smyth M.J. Immune-mediated dormancy: an equilibrium with cancer. J Leukocte Biol 84 (2008) 988-993
3. Dhodapkar M.V., Krasovsky J., Osman K., and Geller M.D. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 198 (2003) 1753
4. Frohn C., Höppner M., Schlenke P., Kirchner H., Koritke P., and Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 119 (2002) 660-664
5. Uchida A., Yagita M., Sugiyama H., Hoshino T., and Moore M. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer 34 (1984) 375-381
6. Gonzalez M., San Miguel J.F., Gascon A., Moro M.J., Hernandez J.M., Ortega F., et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol 39 (1992) 84-89
7. Lanier L.L. NK cell recognition. Annu Rev Immunol 23 (2005) 225-274
8. Garrido F., Ruiz-Cabello F., Cabrera T., Pérez-Villar J.J., López-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18 (1997) 89-95
9. Seliger B., Ruiz-Cabello F., and Garrido F. IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101 (2008) 249-276
10. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., and Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93 (1996) 12445-12450
11. Jinushi M., Vanneman M., Munshi N.C., Tai Y.T., Prabhala R.H., and Ritz J. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 105 (2008) 1285-1290
12. Carbone E., Neri P., Mesuraca M., Fulciniti M.T., Otsuki T., and Pende D. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105 (2005) 251-258
13. Shi J., Tricot G.J., Garg T.K., Malaviarachchi P.A., Szmania S.M., Kellum R.E., et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111 (2008) 1309-1317
14. Ebert E.C., and Groh V. Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology 124 (2008) 33-41
15. Landowski T.H., Qu N., Buyuksal I., Painter J.S., and Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90 (1997) 4266-4270
16. Chappell D.B., Zaks T.Z., Rosenberg S.A., and Restifo N.P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 59 (1999) 59-62